Keros Therapeutics Inc (KROS)
16.42
-0.39
(-2.32%)
USD |
NASDAQ |
Dec 27, 16:00
16.42
0.00 (0.00%)
After-Hours: 20:00
Keros Therapeutics Research and Development Expense (Quarterly): 49.22M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Aptevo Therapeutics Inc | 3.103M |
| Corcept Therapeutics Inc | 59.34M |
| Regeneron Pharmaceuticals Inc | 1.272B |
| Scholar Rock Holding Corp | 48.72M |
| Trevi Therapeutics Inc | 11.22M |